Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

Cerebrospinal fluid biomarkers for clinical trials: why markers for differential diagnosis are important.

Perrin RJ.

Arch Neurol. 2012 Nov;69(11):1407-8. No abstract available.

PMID:
22926002
2.

Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.

Hall S, Öhrfelt A, Constantinescu R, Andreasson U, Surova Y, Bostrom F, Nilsson C, Håkan W, Decraemer H, Någga K, Minthon L, Londos E, Vanmechelen E, Holmberg B, Zetterberg H, Blennow K, Hansson O.

Arch Neurol. 2012 Nov;69(11):1445-52.

PMID:
22925882
3.

CSF α-synuclein as a diagnostic biomarker for Parkinson disease and related dementias.

Ballard CG, Jones EL.

Neurology. 2010 Nov 16;75(20):1760-1. doi: 10.1212/WNL.0b013e3181fd6393. No abstract available.

PMID:
20962288
4.

Tau protein, beta-amyloid₁₋₄₂ and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia.

Vranová HP, Hényková E, Kaiserová M, Menšíková K, Vaštík M, Mareš J, Hluštík P, Zapletalová J, Strnad M, Stejskal D, Kaňovský P.

J Neurol Sci. 2014 Aug 15;343(1-2):120-4. doi: 10.1016/j.jns.2014.05.052.

PMID:
24928081
5.

Combined dementia-risk biomarkers in Parkinson's disease: a prospective longitudinal study.

Compta Y, Pereira JB, Ríos J, Ibarretxe-Bilbao N, Junqué C, Bargalló N, Cámara A, Buongiorno M, Fernández M, Pont-Sunyer C, Martí MJ.

Parkinsonism Relat Disord. 2013 Aug;19(8):717-24. doi: 10.1016/j.parkreldis.2013.03.009. Erratum in: Parkinsonism Relat Disord. 2013 Nov;19(11):1071-2.

PMID:
23643469
6.

Value of cerebrospinal fluid α-synuclein species as biomarker in Parkinson's diagnosis and prognosis.

Parnetti L, Cicognola C, Eusebi P, Chiasserini D.

Biomark Med. 2016;10(1):35-49. doi: 10.2217/bmm.15.107. Review.

7.

Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease.

Bäckström DC, Eriksson Domellöf M, Linder J, Olsson B, Öhrfelt A, Trupp M, Zetterberg H, Blennow K, Forsgren L.

JAMA Neurol. 2015 Oct;72(10):1175-82. doi: 10.1001/jamaneurol.2015.1449.

PMID:
26258692
8.

CSF somatostatin-like immunoreactivity in dementia of Parkinson's disease.

Poewe W, Benke T, Karamat E, Schelosky L, Wagner M, Sperk G.

J Neurol Neurosurg Psychiatry. 1990 Dec;53(12):1105-6. No abstract available.

9.

CSF and clinical hallmarks of subcortical dementias: focus on DLB and PDD.

Stefani A, Brusa L, Olivola E, Pierantozzi M, Martorana A.

J Neural Transm (Vienna). 2012 Jul;119(7):861-75. doi: 10.1007/s00702-012-0820-0. Review.

PMID:
22622365
10.

Ceruloplasmin is increased in cerebrospinal fluid in Alzheimer's disease but not Parkinson's disease.

Loeffler DA, DeMaggio AJ, Juneau PL, Brickman CM, Mashour GA, Finkelman JH, Pomara N, LeWitt PA.

Alzheimer Dis Assoc Disord. 1994 Fall;8(3):190-7.

PMID:
7986488
11.

Concentration of neural thread protein in cerebrospinal fluid from progressive supranuclear palsy and Parkinson's disease.

Yamada T, Chong JK, Asahina M, Koguchi Y, Hirayama K.

Jpn J Psychiatry Neurol. 1993 Sep;47(3):631-5.

PMID:
8301879
12.

Cerebrospinal fluid inflammatory markers in Parkinson's disease--associations with depression, fatigue, and cognitive impairment.

Lindqvist D, Hall S, Surova Y, Nielsen HM, Janelidze S, Brundin L, Hansson O.

Brain Behav Immun. 2013 Oct;33:183-9. doi: 10.1016/j.bbi.2013.07.007.

13.

Orthostatic hypotension is associated with decreased cerebrospinal fluid levels of chromogranin A in early stage of Parkinson disease.

Kaiserova M, Prikrylova Vranova H, Galuszka J, Stejskal D, Mensikova K, Zapletalova J, Mares J, Kanovsky P.

Clin Auton Res. 2015 Oct;25(5):339-42. doi: 10.1007/s10286-015-0302-1.

PMID:
26359267
14.

The influence of cerebrospinal fluid (CSF) biomarkers on clinical dementia evaluations.

Gooblar J, Carpenter BD, Coats MA, Morris JC, Snider BJ.

Alzheimers Dement. 2015 May;11(5):533-540.e2. doi: 10.1016/j.jalz.2014.04.517.

16.

Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.

Parnetti L, Tiraboschi P, Lanari A, Peducci M, Padiglioni C, D'Amore C, Pierguidi L, Tambasco N, Rossi A, Calabresi P.

Biol Psychiatry. 2008 Nov 15;64(10):850-5. doi: 10.1016/j.biopsych.2008.02.016.

PMID:
18395699
17.

Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias.

Parnetti L, Chiasserini D, Bellomo G, Giannandrea D, De Carlo C, Qureshi MM, Ardah MT, Varghese S, Bonanni L, Borroni B, Tambasco N, Eusebi P, Rossi A, Onofrj M, Padovani A, Calabresi P, El-Agnaf O.

Mov Disord. 2011 Jul;26(8):1428-35. doi: 10.1002/mds.23670.

PMID:
21469206
18.

Increased CSF biomarkers of angiogenesis in Parkinson disease.

Janelidze S, Lindqvist D, Francardo V, Hall S, Zetterberg H, Blennow K, Adler CH, Beach TG, Serrano GE, van Westen D, Londos E, Cenci MA, Hansson O.

Neurology. 2015 Nov 24;85(21):1834-42. doi: 10.1212/WNL.0000000000002151.

19.

Biomarkers in dementia: clinical utility and new directions.

Ahmed RM, Paterson RW, Warren JD, Zetterberg H, O'Brien JT, Fox NC, Halliday GM, Schott JM.

J Neurol Neurosurg Psychiatry. 2014 Dec;85(12):1426-34. doi: 10.1136/jnnp-2014-307662. Review.

20.

Cerebrospinal fluid biomarker supported diagnosis of Creutzfeldt-Jakob disease and rapid dementias: a longitudinal multicentre study over 10 years.

Stoeck K, Sanchez-Juan P, Gawinecka J, Green A, Ladogana A, Pocchiari M, Sanchez-Valle R, Mitrova E, Sklaviadis T, Kulczycki J, Slivarichova D, Saiz A, Calero M, Knight R, Aguzzi A, Laplanche JL, Peoc'h K, Schelzke G, Karch A, van Duijn CM, Zerr I.

Brain. 2012 Oct;135(Pt 10):3051-61. doi: 10.1093/brain/aws238.

Items per page

Supplemental Content

Support Center